Circulating and PBMC Lp-PLA 2 associate differently with oxidative stress and subclinical inflammation in nonobese women (menopausal status)

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Paik, Jean Kyung ^a   Kim, Ji Young ^a   Kim, Oh Yoen ^a   Lee, Yonghee ^a   Jeong, Tae Sook ^b   Sweeney, Gary ^c,e   Jang, Yangsoo ^a,d   Lee, Jong Ho ^a  

^a Yonsei University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Institute Pasteur Korea   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; UPREGULATION; BLOOD; BODY WEIGHT; CASE CONTROL STUDY; CHEMISTRY; COMPARATIVE STUDY; MENOPAUSE; MIDDLE AGED; MONONUCLEAR CELL; PHYSIOLOGY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; BIOLOGICAL MARKERS; BODY WEIGHT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; LIPOPROTEINS, LDL; MENOPAUSE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 84863163396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029675     Document Type: Article

References (42)

1. Zalewski A, Macphee C, (2005) Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25: 923-931.
2. Caslake MJ, Packard CJ, (2003) Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 14: 347-352.
3. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, et al. (1999) Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 338: 479-487.
4. Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, et al. (2008) The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 51: 1632-1641.
5. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, et al. (2000) Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343: 1148-1155.
6. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, et al. (2005) Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111: 570-575.
7. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, et al. (2005) Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 111: 980-987.
8. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, et al. (2006) Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 26: 2517-2522.
9. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, et al. (2005) Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26: 137-144.
10. Winkler K, Hoffmann MM, Winkelmann BR, Friedrich I, Schäfer G, et al. (2007) Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Clin Chem 53: 1440-1447.
11. Kim JY, Hyun YJ, Jang Y, Lee BK, Chae JS, et al. (2008) Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. Am J Clin Nutr 88: 630-637.
12. Hatoum IJ, Nelson JJ, Cook NR, Hu FB, Rimm EB, (2010) Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr 91: 786-793.
13. Detopoulou P, Nomikos T, Fragopoulou E, Panagiotakos DB, Pitsavos C, et al. (2009) Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults. Lipids Health Dis 8: 19.
14. Koenig W, Khuseyinova N, Löwel H, Trischler G, Meisinger C, (2004) Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110: 1903-1908.
15. Persson M, Nilsson JA, Nelson JJ, Hedblad B, Berglund G, (2007) The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 190: 388-396.
16. Iribarren C, Gross MD, Darbinian JA, Jacobs DR Jr, Sidney S, et al. (2005) Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 25: 216-221.
17. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, et al. (2005) Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 165: 2479-2484.
18. Yang EH, McConnell JP, Lennon RJ, Barsness GW, Pumper G, et al. (2006) Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 26: 106-111.
19. Khuseyinova N, Imhof A, Rothenbacher D, Trischler G, Kuelb S, et al. (2005) Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 182: 181-188.
20. De Keyzer D, Karabina SA, Wei W, Geeraert B, Stengel D, et al. (2009) Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol 29: 2041-2046.
21. Wang WY, Li J, Yang D, Xu W, Zha RP, et al. (2010) OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways. Cardiovasc Res 85: 845-852.
22. Rachoń D, Myśliwska J, Suchecka-Rachoń K, Wieckiewicz J, Myśliwski A, (2002) Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. J Endocrinol 172: 387-395.
23. von Haehling S, Genth-Zotz S, Sharma R, Bolger AP, Doehner W, et al. (2003) The relationship between age and production of tumour necrosis factor-alpha in healthy volunteers and patients with chronic heart failure. Int J Cardiol 90: 197-204.
24. Shi Y, Zhang P, Zhang L, Osman H, Mohler ER 3rd, et al. (2007) Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 191: 54-62.
25. Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, et al. (1999) Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 261: 511-514.
26. Tarbet EB, Stafforini DM, Elstad MR, Zimmerman GA, McIntyre TM, et al. (1991) Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase. J Biol Chem 266: 16667-16673.
27. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M, (2003) Plasma platelet activating factor-acetylhydrolase (PAF-AH). Progress in Lipid Research 42: 93-114.
28. Ninio E, (2005) Phospholipid mediators in the vessel wall: involvement in atherosclerosis. Curr Opin Clin Nutr Metab Care 8: 123-131.
29. Carpenter KL, Dennis IF, Challis IR, Osborn DP, Macphee CH, et al. (2001) Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett 505: 357-363.
30. Karabina SA, Ninio E, (2006) Plasma PAF-acetylhydrolase: an unfulfilled promise?. Biochim Biophys Acta 1761: 1351-1358.
31. Silva IT, Mello AP, (2011) Damasceno NR. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2): a review. Lipids Health Dis [Epub ahead of print].
32. Six DA, Dennis EA, (2000) The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 1488: 1-19.
33. Tsaoussis V, Vakirtzi-Lemonias C, (1994) The mouse plasma PAF acetylhydrolase: II. It consists of two enzymes both associated with the HDL. J Lipid Mediat Cell Signal 9: 317-331.
34. Liapikos TA, Antonopoulou S, Karabina SP, Tsoukatos DC, Demopoulos CA, Tselepis AD, (1994) Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim Biophys Acta 1212: 353-360.
35. Stafforini DM, Sheller JR, Blackwell TS, Sapirstein A, Yull FE, et al. (2006) Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J Biol Chem 281: 4616-4623.
36. Kono N, Inoue T, Yoshida Y, Sato H, Matsusue T, et al. (2008) Protection against oxidative stress-induced hepatic injury by intracellular type II PAF-acetylhydrolase by metabolism of oxidized phospholipids in vivo. J Biol Chem 283: 1628-1636.
37. Caivano M, Cohen P, (2000) Role of mitogen-activated protein kinase cascades in mediating lipopolysaccharide-stimulated induction of cyclooxygenase-2 and IL-1 beta in RAW264 macrophages. J Immunol 164: 3018-3025.
38. Ershler WB, Keller ET, (2000) Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 51: 245-270.
39. Liu H, Liu K, Bodenner DL, (2005) Estrogen receptor inhibits interleukin-6 gene expression by disruption of nuclear factor-κB transactivation. Cytokine 31: 251-257.
40. Ray P, Ghosh SK, Zhang DH, Ray A, (1997) Repression of interleukin-6 gene expression by 17 b-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-κB by the estrogen receptor. FEBS Lett 409: 79-85.
41. Papanicolaou DA, Vgontzas AN, (2000) Interleukin-6: the endocrine cytokine. J Clin Endocrinol Metab 85: 1331-1333.
42. Paik JK, Chae JS, Jang Y, Kim JY, Kim OY, Jeong TS, et al. (2010) Effects of V279F in the Lp-PLA2 gene on markers of oxidative stress and inflammation in Koreans. Clin Chim Act 411: 486-493.